

68 1651

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
UNITED STATES RECEIVING OFFICE (RO/US)

Application of: Segal

Serial No.: 09/345,148

Filed: June 30, 1999

Entitled: CD40 Ligand Enhanced Cells and Methods
of Modulating an Immune Response to an
Antigen

RECEIVED
NOV 17 1999
TECH CENTER 1600/2900

Atty. Docket No.: 3378/80490

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98

Dear Sir:


In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list. Pursuant to 37 C.F.R. § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicants respectfully request that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

11/16/99
Date


Kathleen M. Williams, Ph.D.
Reg. No. 34,380
Attorney of Record
BANNER & WITCOFF, LTD.
28 State Street
Boston, Massachusetts 02109
Telephone: (617) 227-7111
Telecopier: (617) 227-4399